The collagen fragment your body already makes — with genuine human clinical data, a dual anti-aging mechanism, both topical and oral evidence, and the strongest biological rationale in the cosmetic peptide cluster

In a cluster full of synthetic peptides designed to mimic biological processes, Tripeptide-29 is the real thing. Gly-Pro-Hyp — glycine-proline-hydroxyproline — is not an invention of cosmetic chemistry. It is the most frequently occurring tripeptide repeat in the human collagen triple helix, appearing approximately 35 times per alpha chain of type I collagen. When collagen is degraded by matrix metalloproteinases during photoaging, wound healing, or normal tissue turnover, Gly-Pro-Hyp fragments are released into the extracellular space. Those fragments function as matrikines — signaling peptides that tell dermal fibroblasts to start synthesizing new collagen.

The evidence base is more substantial than any other compound in Cluster G. A prospective human study using topical collagen tripeptide showed measurable improvements in wrinkle depth, elasticity, and skin density at four weeks. Multiple randomized controlled trials of oral collagen peptide supplements enriched in Gly-Pro-Hyp demonstrated improved hydration, wrinkle reduction, and elasticity over 12 weeks. And a distinct anti-aging mechanism — glycation inhibition — has been demonstrated in vitro, suggesting the peptide works on two fronts simultaneously.

The limitations are real but narrow. The topical study is a pilot without a control group. The oral studies test multi-component collagen hydrolysates, not isolated Gly-Pro-Hyp, so the specific contribution of this tripeptide versus other fragments is uncertain. And topical penetration, while better than most cosmetic peptides (the molecule is only ~285 daltons), still delivers less than 7% of applied peptide to the dermis in lab models.

For a deeper understanding of how topical peptides navigate the skin barrier — and how oral collagen supplementation compares to topical delivery — see our [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/) guide.

Quick Facts: Tripeptide-29 at a Glance

What Is Tripeptide-29? — Origins and Discovery

Pronunciation: try-PEP-tide twenty-nine

Your skin is built on collagen. Roughly 75% of the dry weight of human dermis is collagen — a triple-helix protein that forms the structural scaffold giving skin its firmness, elasticity, and mechanical strength. That triple helix is built from repeating Gly-X-Y triplets, and the single most common triplet in the entire structure is glycine-proline-hydroxyproline — Gly-Pro-Hyp. It appears approximately 35 times in every alpha-1(I) collagen chain, making it the molecular signature of the most abundant protein in the human body.

When collagen degrades — from UV exposure, from aging, from the slow enzymatic turnover of tissue maintenance — the breakdown products include Gly-Pro-Hyp fragments. These fragments are not waste. They are signals. Collagen-derived matrikines tell nearby fibroblasts: "Collagen was just degraded here. Synthesize more." The body has been using Gly-Pro-Hyp as a repair signal for as long as vertebrates have had collagen — which is to say, for hundreds of millions of years.

Tripeptide-29 is the cosmetic industry's name for this molecule. Unlike Argireline (which mimics a botulinum toxin target), Matrixyl (which is a synthetic fragment of a collagen-regulating protein), or Syn-Ake (which claims to mimic snake venom), Tripeptide-29 does not borrow its biology from somewhere else. It is the biology. The question is not whether Gly-Pro-Hyp has biological activity — it does, and that activity is well-characterized. The question is whether topical or oral delivery provides enough of it, in the right place, to produce measurable skin improvement.

Mechanism of Action

Matrikine Signaling: Collagen Talks to Fibroblasts

Gly-Pro-Hyp operates through a matrikine feedback loop. When matrix metalloproteinases (MMPs) cleave collagen during tissue remodeling, the released Gly-Pro-Hyp fragments act as chemotactic and mitogenic signals for dermal fibroblasts:

1. Fibroblast chemotaxis — Gly-Pro-Hyp attracts fibroblasts to sites of collagen degradation, ensuring that repair cells accumulate where they are needed.

2. Collagen I synthesis — Fibroblasts exposed to collagen-derived tripeptides upregulate procollagen I gene expression and protein production. The related dipeptide Pro-Hyp (a Gly-Pro-Hyp metabolite) stimulates approximately 1.5-fold fibroblast proliferation in culture (PMID 20507402).

3. Hyaluronic acid production — Pro-Hyp stimulates a 3.8-fold increase in hyaluronic acid synthesis in cultured human dermal fibroblasts (PMID 20507402). HA is the primary water-binding molecule in the dermis; increased HA content improves skin hydration and plumpness.

4. MMP suppression — Collagen tripeptide treatment reduces expression of MMP-2, MMP-3, MMP-9, and MMP-13 in UV-exposed skin (PMID 24471092). This slows further collagen degradation — a "brake" on the same process that generated the tripeptide signal in the first place.

Anti-Glycation: A Second Anti-Aging Mechanism

Glycation — the non-enzymatic cross-linking of collagen fibers by reducing sugars — is a major driver of skin aging that accumulates over decades. Advanced glycation end-products (AGEs) make collagen stiff, brittle, and resistant to normal turnover. In vitro, collagen tripeptide treatment reduced AGE accumulation and reactive oxygen species in dermal fibroblasts (PMID 35163025). This represents a distinct anti-aging pathway beyond simple collagen stimulation: the peptide not only promotes new collagen synthesis but may also protect existing collagen from glycation damage.

The GPVI Interaction: A Footnote, Not a Concern

Gly-Pro-Hyp is uniquely specific for platelet glycoprotein VI (GPVI), the primary collagen receptor on platelets (PMID 10341844). This interaction mediates platelet activation during hemostasis. At cosmetic topical concentrations, systemic absorption is negligible, making this clinically irrelevant. For oral supplementation, the low bioavailability (4.4%) and rapid clearance make systemic platelet effects unlikely at standard supplement doses.

Key Research Areas and Studies

Human Topical Evidence

Lee et al. (2022) — PMID 35163025: Prospective pilot study, 22 subjects, 4 weeks, topical collagen tripeptide cream. Results: significant improvement in wrinkle depth (measured by replica analysis), skin elasticity (Cutometer), and skin density (ultrasound). Additionally, the in vitro component showed reduced AGE accumulation and ROS in fibroblast cultures treated with collagen tripeptide.

Limitation: Single-arm study with no placebo control. Improvements could reflect the vehicle (cream base), natural variation, or placebo effect. A controlled study with the same formulation versus vehicle alone is needed.

Human Oral Evidence

Tak et al. (2021) — PMID 33521019: Randomized, double-blind, placebo-controlled trial. 84 subjects, 12 weeks, oral collagen tripeptide (CTP) supplement containing 3.2% Gly-Pro-Hyp. Results: significant reduction in transepidermal water loss (TEWL) versus placebo — indicating improved skin barrier function. The oral supplement reached the skin from the inside.

Kim et al. (2018) — PMID 29949889: Randomized, double-blind, placebo-controlled trial. 64 subjects, 12 weeks, oral low-molecular-weight collagen peptide (LMWCP) containing >3% Gly-Pro-Hyp. Results: significant improvement in skin hydration and wrinkle depth versus placebo.

Choi et al. (2014) — PMID 24131075: Randomized, single-blind trial. 32 subjects, 12 weeks, oral collagen peptide. Results: improved hydration and elasticity. Collagen peptide composition not fully specified; Gly-Pro-Hyp content estimated from general collagen hydrolysate profiles.

The Attribution Problem

All oral studies test collagen hydrolysate formulations that contain Gly-Pro-Hyp as one component among many collagen fragments. The specific contribution of Gly-Pro-Hyp versus Pro-Hyp, Gly-Pro, Hyp-Gly, and other bioactive fragments is unknown. This is the same "combination product" attribution problem seen with Matrixyl 3000, but the biological context is different: Gly-Pro-Hyp is the most abundant specific tripeptide in collagen and the most likely to reach skin fibroblasts intact (confirmed by pharmacokinetic data).

Animal Evidence

Pyun et al. (2012) — PMID 24471092: UVB-exposed hairless mice treated with oral collagen tripeptide showed reduced wrinkle formation, improved barrier function (40.5% TEWL reduction), and inhibited MMP-2/-3/-9/-13 expression. This supports the dual mechanism: collagen stimulation + MMP suppression.

Sontakke et al. (2016) — PMID 27573716: Pharmacokinetic study in rats. Oral Gly-Pro-Hyp is absorbed intact (not fully degraded by GI enzymes) with 4.4% oral bioavailability. Confirms the peptide survives digestion and enters systemic circulation.

Two Routes, One Target — Topical Vs. Oral Delivery

A Unique Position in Cluster G

Tripeptide-29 is the only Cluster G compound with published human evidence for both topical and oral delivery routes. This dual evidence base is significant because it addresses the topical penetration challenge from two directions.

Topical Delivery

Advantages: Direct application to the target tissue. The ~285 Da molecular weight is below the 500 Da skin permeation threshold — the best penetration profile in Cluster G. Franz diffusion cell studies show approximately 6.74% penetration of intact tripeptide through skin.

Limitations: 6.74% is better than most Cluster G peptides but still means >93% of applied peptide stays on the surface. Whether the penetrating fraction reaches dermal fibroblasts in sufficient concentration to trigger collagen synthesis is unresolved.

Oral Delivery

Advantages: Bypasses the stratum corneum entirely. Gly-Pro-Hyp survives GI digestion and enters systemic circulation intact (4.4% bioavailability in rats — PMID 27573716). Blood-borne collagen peptides reach the dermis via the microvasculature, delivering the signal to fibroblasts from the inside.

Limitations: Low oral bioavailability (4.4%) means most of the ingested peptide is metabolized before reaching systemic circulation. Whether the fraction that reaches skin is sufficient for a meaningful effect depends on dose, with clinical studies using 1,000–3,000 mg/day of total collagen peptide.

The Complementary Argument

Topical delivers directly but with limited penetration. Oral delivers systemically but with low bioavailability. The two approaches may complement each other — and some consumers use both simultaneously — but no study has tested topical + oral versus either alone.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Real Evidence, Real Limitations

Tripeptide-29 has the strongest human evidence base in Cluster G — but "strongest in Cluster G" is a relative claim in a cluster where the bar is low.

Topical Evidence

The Lee et al. (2022) pilot study (PMID 35163025) is the only published human trial of topical collagen tripeptide. Twenty-two subjects, four weeks, measurable improvements in wrinkle depth, elasticity, and density. The limitation: no control group. Without a placebo comparison, the contribution of the cream base (emollients, moisturizers) versus the active tripeptide cannot be separated.

Oral Evidence

Multiple RCTs with placebo controls demonstrate consistent improvements in skin hydration, TEWL, wrinkle depth, and elasticity at 12 weeks. The Tak et al. (2021) study (N=84, PMID 33521019) is the largest and most rigorous. The limitation: these studies test collagen hydrolysate formulations containing Gly-Pro-Hyp (3–15% of total) alongside other collagen fragments. The specific contribution of Gly-Pro-Hyp is inferred but not isolated.

What Makes This Different from Other Attribution Problems

The Matrixyl 3000 attribution problem (is it Pal-GHK or Pal-GQPR?) involves two ingredients with very different evidence weights. The collagen supplement attribution problem is different: Gly-Pro-Hyp is the most abundant specific tripeptide in the hydrolysate, and pharmacokinetic data confirms it survives digestion and enters systemic circulation intact. The circumstantial case for Gly-Pro-Hyp as a primary active component is stronger than for most combination-product ingredients.

What Would Advance the Evidence

1. A randomized, placebo-controlled trial of topical Tripeptide-29 versus vehicle (the most impactful single study) 2. A dose-finding study for oral Gly-Pro-Hyp in isolation 3. A head-to-head comparison of collagen hydrolysate with and without Gly-Pro-Hyp enrichment

Safety, Risks, and Limitations

Excellent Safety Profile

Tripeptide-29 has the most straightforward safety case in Cluster G: it is composed of three amino acids (glycine, proline, hydroxyproline) that are already abundant in human metabolism and diet. Collagen peptides have GRAS (Generally Recognized as Safe) status for food use.

Dermal safety: No irritation or adverse effects in the topical pilot study (N=22, 4 weeks). Oral safety: No adverse effects in oral RCTs (N=32–84, up to 12 weeks). Collagen supplements have extensive safety records from food/supplement use. Allergic potential: Extremely unlikely given endogenous amino acid composition. Formulation excipients may occasionally cause reactions. Systemic exposure: Low from topical; measurable but limited from oral (4.4% bioavailability in rats).

Platelet GPVI Interaction: A Theoretical Note

Gly-Pro-Hyp activates platelet glycoprotein VI (PMID 10341844). This interaction mediates platelet activation by collagen — a normal hemostatic process. At cosmetic topical concentrations, systemic absorption is negligible and this interaction is clinically irrelevant. For oral supplementation at standard doses (1,000–3,000 mg/day total collagen peptide, of which 3–15% is Gly-Pro-Hyp), the low bioavailability makes systemic platelet effects highly unlikely. No clinical reports of bleeding or clotting complications exist. Theoretical caution may apply for patients on antiplatelet therapy, but this has not been clinically evaluated.

Legal and Regulatory Status

FDA Classification

Topical Tripeptide-29 is a cosmetic ingredient. Oral collagen peptides containing Gly-Pro-Hyp have GRAS status for food and supplement use. Neither formulation is FDA-approved as a drug.

International Status

Accepted for cosmetic use in the European Union (EC 1223/2009) and globally. Collagen peptide supplements are available OTC worldwide with no restrictions.

WADA Status

Not prohibited. Nutritional supplement and cosmetic ingredient with no ergogenic potential.

Research Protocols and Formulation Considerations

Topical Formulation

Tripeptide-29 is available from cosmetic ingredient suppliers as a concentrated solution or powder. Typical inclusion in finished products: 0.001–0.5% active peptide. At ~285 Da, it has the smallest molecular weight in Cluster G and the best theoretical penetration profile.

Oral Formulation

Collagen tripeptide supplements are available as hydrolyzed collagen powders, capsules, and liquid supplements. Clinical study doses: 1,000–3,000 mg/day total collagen peptide. Gly-Pro-Hyp content varies by product (3–15% of total).

Stability

Small peptide, susceptible to protease degradation in the stratum corneum (topical) and GI tract (oral). Formulation-dependent. Topical products should buffer to pH 4.5–6.5. Oral pharmacokinetics show the tripeptide survives digestion better than expected for its size class (PMID 27573716).

Delivery Enhancement

Topical delivery may be enhanced by microneedling, liposomal encapsulation, or penetration enhancers. The ~285 Da molecular weight is already below the 500 Da permeation threshold, giving Tripeptide-29 a delivery advantage over larger Cluster G peptides.

For comprehensive guidance on topical peptide delivery, see [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/).

Dosing in Published Research

Published Dose Data

No Isolated Dose-Response Study

No published study compares different concentrations of isolated Tripeptide-29 (topical or oral) to determine optimal dosing.

Dosing in Self-Experimentation Communities

Community Usage Patterns

Community Perception

Tripeptide-29 benefits from the broader collagen supplement trend. Oral collagen peptides are among the most mainstream supplements in the skincare community, driven by consistent consumer reports of improved skin hydration and hair/nail quality. The specific INCI name "Tripeptide-29" is less well-known than the general "collagen peptide" category — many consumers take Gly-Pro-Hyp daily without knowing it by this name.

Combination Stacks

Research into Tripeptide-29 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Tripeptide-29 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Related Compounds: How Tripeptide-29 Compares

Tripeptide-29 belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Skin & Cosmetic cluster.

Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
Argireline	Acetyl Hexapeptide-3 (Ac-EEMQRR-NH2); 889 Da	Tier 3 — Limited Human Data	Reasonable Bet	SNAP-25 mimetic → inhibits SNARE complex assembly → reduces ACh release at NMJ; topical 'botox-like' effect without cleaving SNARE	Expression wrinkle reduction; forehead and crow's feet	~200 in clinical studies; 10–30% wrinkle reduction in 4 weeks	Not approved as drug (cosmetic ingredient; INCI listed)	Not prohibited	Penetration to dermal-epidermal junction unproven; effect magnitude far less than injectable botulinum toxin; manufacturer-sponsored studies
Matrixyl	Palmitoyl Pentapeptide-4 (Pal-KTTKS); 802 Da	Tier 3 — Limited Human Data	Reasonable Bet	Matrikine signaling — KTTKS collagen fragment stimulates fibroblast collagen I/III/IV synthesis + fibronectin + glycosaminoglycans; palmitoyl enhances penetration	Wrinkle reduction; collagen stimulation; skin texture improvement	~150 in clinical studies; comparable to retinol in head-to-head	Not approved as drug (cosmetic ingredient)	Not prohibited	Primarily manufacturer-sponsored studies; independent validation limited; comparisons to retinol, not vehicle alone
Matrixyl 3000	Palmitoyl Tetrapeptide-7 + Palmitoyl Tripeptide-1 (Pal-GQPR + Pal-GHK); blend	Tier 3 — Limited Human Data	Reasonable Bet	Dual action: Pal-GHK (matrikine collagen stimulation) + Pal-GQPR (IL-6 suppression + MMP-1 inhibition); build collagen while preventing degradation	Wrinkle reduction; anti-aging; skin firmness	~120 in clinical studies; 22–28% wrinkle reduction	Not approved as drug (cosmetic ingredient)	Not prohibited	Proprietary blend (exact ratios undisclosed); primarily manufacturer data; less independent validation than Matrixyl
SNAP-8	Acetyl Octapeptide-3 (Ac-EEMQRRAD-NH2); 1,075 Da	Tier 4 — Preclinical Only	Eyes Open	Extended SNAP-25 mimetic (8 vs 6 AA); claimed greater SNARE inhibition than Argireline; same mechanism, additional binding contacts	Expression wrinkle reduction (claimed superior to Argireline)	None — zero peer-reviewed human studies	Not approved as drug (cosmetic ingredient)	Not prohibited	Zero published human efficacy data; larger MW may worsen skin penetration; marketed as 'superior' without human validation
Leuphasyl	Pentapeptide-18 (Tyr-D-Ala-Gly-Phe-Leu); 569 Da; enkephalin analog	Tier 4 — Preclinical Only	Thin Ice	Mu-opioid receptor agonist on sensory nerve terminals → reduces ACh release via presynaptic inhibition; different upstream mechanism than Argireline	Expression wrinkle reduction (Argireline synergist)	None — zero published human studies	Not approved as drug (cosmetic ingredient)	Not prohibited	Opioid receptor agonist topically — penetration to dermal nerve terminals undemonstrated; no independent data; marketed only as Argireline booster
Palmitoyl Tripeptide-1	Pal-GHK (Biopeptide-CL); 578 Da	Tier 3 — Limited Human Data	Reasonable Bet	GHK matrikine signaling → fibroblast collagen synthesis + ECM remodeling; palmitoyl enhances skin penetration; GHK-Cu without the copper	Collagen stimulation; anti-aging; wound healing signal	~80 in clinical studies (mostly in Matrixyl 3000 combo)	Not approved as drug (cosmetic ingredient)	Not prohibited	Usually studied in combination (Matrixyl 3000); hard to isolate individual contribution; GHK-Cu has more independent research
Palmitoyl Tetrapeptide-7	Pal-GQPR; 687 Da; IgG fragment mimic	Tier 3 — Limited Human Data	Eyes Open	Anti-inflammatory: reduces IL-6 keratinocyte secretion + suppresses UVB inflammation + inhibits MMP-1 collagenase expression	Anti-inflammatory; collagen preservation; UVB damage reduction	~60 (only as part of Matrixyl 3000 combination)	Not approved as drug (cosmetic ingredient)	Not prohibited	Never studied independently of Pal-GHK partner; clinical contribution unknown; anti-inflammatory mechanism plausible but unvalidated alone
Syn-Ake	Dipeptide Diaminobutyroyl Benzylamide Diacetate; ~390 Da	Tier 4 — Preclinical Only	Eyes Open	Claimed nAChR antagonism mimicking waglerin-1 (temple viper venom) → muscle relaxation → reduced expression lines	Expression wrinkle reduction ('snake venom–inspired')	1 unpublished manufacturer panel study (~45 subjects)	Not approved as drug (cosmetic ingredient)	Not prohibited	Marketing narrative ('snake venom') far exceeds evidence; structural resemblance to waglerin-1 is minimal; zero peer-reviewed data; nAChR blockade unverified
Acetyl Tetrapeptide-5	Ac-β-Ala-His-Ser-His (Eyeseryl); ~493 Da	Tier 4 — Preclinical Only	Eyes Open	Anti-edema: reduces vascular permeability + fluid accumulation; anti-glycation of capillary walls; targets periorbital puffiness	Under-eye puffiness (de-puffing); periorbital application	None — manufacturer panel data only (unpublished)	Not approved as drug (cosmetic ingredient)	Not prohibited	No peer-reviewed evidence; mechanism (anti-edema via glycation inhibition) is speculative; marketed for very specific niche (eye bags)
Palmitoyl Hexapeptide-12	Palmitoyl Hexapeptide-12; ~921 Da	Tier 4 — Preclinical Only	Thin Ice	Proposed collagen + hyaluronic acid synthesis stimulation; adhesion molecule expression for dermal-epidermal junction integrity	Anti-aging; collagen stimulation (unvalidated)	None — zero evidence of any kind	Not approved as drug (cosmetic ingredient)	Not prohibited	Zero peer-reviewed data; no mechanism validation; no manufacturer claims with detail; exists on ingredient lists by category association only
AHK-Cu	Ala-His-Lys-Cu²⁺; ~428 Da; copper tripeptide	Tier 4 — Preclinical Only	Thin Ice	Copper tripeptide signaling → proposed collagen/elastin synthesis via LOX activation; GHK-Cu analog with different N-terminal residue	Hair growth; wound healing; collagen stimulation	None — zero published human studies for AHK-Cu specifically	Not approved as drug (cosmetic ingredient)	Not prohibited	Evidence borrowed from GHK-Cu; no independent validation for AHK specifically; alanine substitution impact unknown; most marketing cites GHK-Cu data
Tripeptide-29	Gly-Pro-Hyp (collagen tripeptide); ~285 Da	Tier 3 — Limited Human Data	Reasonable Bet	Matrikine signaling — most abundant collagen repeat; stimulates fibroblast collagen I synthesis + anti-glycation (AGE reduction) + MMP inhibition	Collagen stimulation; anti-aging; anti-glycation; skin hydration	~202 across 4 studies (1 topical pilot N=22; 3 oral RCTs N=32–84)	Not approved as drug (cosmetic/GRAS ingredient)	Not prohibited	Topical study uncontrolled; oral RCTs test multi-component hydrolysates (3–15% Gly-Pro-Hyp), not isolated tripeptide; low oral bioavailability (4.4%)

Frequently Asked Questions

Summary of Key Findings

Tripeptide-29 (Gly-Pro-Hyp) is the most abundant tripeptide in human collagen and a natural matrikine — a breakdown product that signals fibroblasts to synthesize new collagen, produce hyaluronic acid, and suppress collagen-degrading enzymes. It also demonstrates anti-glycation activity in vitro, suggesting a dual anti-aging mechanism.

The human evidence base is the strongest in Cluster G. A topical pilot study (N=22, 4 weeks) showed measurable improvements in wrinkle depth, elasticity, and skin density. Multiple oral RCTs (N=32–84, 6–12 weeks) of collagen hydrolysates enriched in Gly-Pro-Hyp demonstrated significant improvements in skin hydration, TEWL, and wrinkle depth versus placebo. Pharmacokinetic data confirms the tripeptide survives oral digestion and enters systemic circulation intact.

The limitations are narrow but real: the topical study lacks a placebo control, and the oral studies test multi-component hydrolysates rather than isolated Gly-Pro-Hyp. The specific contribution of this tripeptide versus other collagen fragments in the supplements is inferred from abundance and pharmacokinetic data, not from isolation studies.

Safety is excellent — three amino acids abundant in normal human metabolism, GRAS status for food use, no adverse effects in any published study.

Verdict Recapitulation

Tripeptide-29 is Cluster G's best case for a cosmetic peptide with genuine biology behind it. It is not a synthetic construct borrowing credibility from a venom or immunoglobulin or signaling pathway it vaguely resembles. It is the actual signal — the most common tripeptide in the most common protein in your body, doing what it has always done: telling skin cells that collagen needs repair. The human evidence is measurable, the safety is impeccable, and the dual mechanism (collagen stimulation plus glycation inhibition) addresses two validated aging pathways simultaneously. What keeps it from "Strong Foundation" is the absence of a large, rigorously controlled trial for the isolated compound. When that study happens, Tripeptide-29 is the Cluster G candidate most likely to graduate.

For readers considering Tripeptide-29, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Tripeptide-29

Further Reading and Resources

If you want to go deeper on Tripeptide-29, the evidence landscape for skin & cosmetic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Skin & Cosmetic Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Tripeptide-29 — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Lee, H.J. et al. (2022). "Effects of collagen tripeptide supplement on skin properties: A prospective, randomized, controlled study." Journal of Cosmetic Dermatology, 21(3), 1269–1277. PMID 35163025
2. Tak, Y.J. et al. (2021). "Effect of oral ingestion of low-molecular collagen peptides derived from skate on skin hydration, elasticity, and wrinkles." Nutrients, 13(11), 3881. PMID 33521019
3. Kim, D.U. et al. (2018). "Oral intake of low-molecular-weight collagen peptide improves hydration, elasticity, and wrinkling in human skin." Nutrients, 10(7), 826. PMID 29949889
4. Choi, S.Y. et al. (2014). "Effects of collagen tripeptide supplement on skin properties: A prospective, randomized, controlled study." Journal of Cosmetic and Laser Therapy, 16(3), 132–137. PMID 24131075
5. Pyun, H.B. et al. (2012). "Effects of collagen tripeptide supplement on photoaging and epidermal skin barrier in UVB-exposed hairless mice." Preventive Nutrition and Food Science, 17(4), 245–253. PMID 24471092
6. Sontakke, S.B. et al. (2016). "Bioavailability of collagen tripeptide (Gly-Pro-Hyp) in rats." International Journal of Food Sciences and Nutrition, 67(8), 919–926. PMID 27573716
7. Ohara, H. et al. (2010). "Collagen-derived dipeptide, proline-hydroxyproline, stimulates cell proliferation and hyaluronic acid synthesis in cultured human dermal fibroblasts." Journal of Dermatology, 37(4), 330–338. PMID 20507402
8. Knight, C.G. et al. (1999). "Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen." Cardiovascular Research, 41(2), 450–457. PMID 10341844

---